The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Jiang, Zhinong ^a   Guo, Junlan ^a   Shen, Jianguo ^a   Jin, Mei ^a   Xie, Shuduo ^a   Wang, Linbo ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Bcl 2; Breast cancer; Cell growth; Chemoresistance; Estrogen receptor alpha

Indexed keywords

ANTIINFECTIVE AGENT; BROMIDE; EPIRUBICIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FLUOROURACIL; FULVESTRANT; NAVELBINE; PACLITAXEL; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2;

ARTICLE; BREAST CANCER; BREAST CANCER CELL; CANCER CELL; CELL CYCLE; CELL GROWTH; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFECTION; UP-REGULATION;

EID: 84865088686     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-42     Document Type: Article

References (31)

1. Relevance of breast cancer cell lines as models for breast tumours: an update. Lacroix M, Leclercq G, Breast Cancer Res Treat 2004 83 249 289 10.1023/B:BREA.0000014042.54925.cc 14758095
2. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A, Bhalla K, Breast Cancer Res Treat 1997 42 73 81 10.1023/A:1005777219997 9116321
3. Estrogenic and antiestrogenic regulation of the half-life of covalently labeled estrogen receptor in MCF-7 breast cancer cells. Borras M, Laios I, el Khissiin A, Seo HS, Lempereur F, Legros N, Leclercq G, J Steroid Biochem Mol Biol 1996 57 203 213 10.1016/0960-0760(95)00272-3 8645630
4. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, et al. JAMA 2006 295 1658 1667 10.1001/jama.295.14.1658 16609087
5. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Colleoni M, Minchella I, Mazzarol G, Nole F, Peruzzotti G, Rocca A, Viale G, Orlando L, Ferretti G, Curigliano G, et al. Ann Oncol 2000 11 1057 1059 10.1023/A:1008334404825 11038046
6. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer. Petit T, Wilt M, Velten M, Rodier JF, Fricker JP, Dufour P, Ghnassia JP, Breast Cancer Res Treat 2010 124 387 391 10.1007/s10549-010-1142-2 20824324
7. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, Isaacs C, Pennanen M, Tibery C, Farhad A, et al. Clin Cancer Res 2003 9 124 133 12538460
8. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Tan MC, Al Mushawah F, Gao F, Aft RL, Gillanders WE, Eberlein TJ, Margenthaler JA, Am J Surg 2009 198 520 525 10.1016/j.amjsurg.2009. 06.004 19800460
9. The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study. Wang L, Jiang Z, Sui M, Shen J, Xu C, Fan W, BMC Cancer 2009 9 226 10.1186/1471-2407-9- 226 19591668
10. Downregulation of Aurora-A overrides estrogen-mediated growth and chemoresistance in breast cancer cells. Lee HH, Zhu Y, Govindasamy KM, Gopalan G, Endocr Relat Cancer 2008 15 765 775 10.1677/ERC-07-0213 18469155
11. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Sui M, Huang Y, Park BH, Davidson NE, Fan W, Cancer Res 2007 67 5337 5344 10.1158/0008-5472.CAN-06-4582 17545614
12. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine. Sui M, Jiang D, Hinsch C, Fan W, Breast Cancer Res Treat 2010 121 335 345 10.1007/s10549-009-0472-4 19626437
13. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Tabuchi Y, Matsuoka J, Gunduz M, Imada T, Ono R, Ito M, Motoki T, Yamatsuji T, Shirakawa Y, Takaoka M, et al. Int J Oncol 2009 34 313 319 19148464
14. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Teixeira C, Reed JC, Pratt MA, Cancer Res 1995 55 3902 3907 7641210
15. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, et al. Lancet 2009 374 2055 2063 10.1016/S0140-6736(09)61523-3 20004966
16. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Pico C, Martin M, Jara C, Barnadas A, Pelegri A, Balil A, Camps C, Frau A, Rodriguez-Lescure A, Lopez-Vega JM, et al. Ann Oncol 2004 15 79 87 10.1093/annonc/mdh016 14679124
17. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Minton JP, Osborne CK, J Clin Oncol 1994 12 2078 2085 7931477
18. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. Penault-Llorca F, Andre F, Sagan C, Lacroix-Triki M, Denoux Y, Verriele V, Jacquemier J, Baranzelli MC, Bibeau F, Antoine M, et al. J Clin Oncol 2009 27 2809 2815 10.1200/JCO.2008.18.2808 19380452
19. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Vincent-Salomon A, Rousseau A, Jouve M, Beuzeboc P, Sigal-Zafrani B, Freneaux P, Rosty C, Nos C, Campana F, Klijanienko J, et al. Eur J Cancer 2004 40 1502 1508 10.1016/j.ejca.2004.03.014 15196533
20. Relationship between Ki67 expression and tumor response to neoadjuvant chemotherapy with anthracyclines plus taxanes in breast cancer. Xu L, Liu YH, Ye JM, Zhao JX, Duan XN, Zhang LB, Zhang H, Wang YH, Zhonghua Wai Ke Za Zhi 2010 48 450 453 20627009
21. Immunohistochemical demonstration of cell proliferation and estrogen receptor status in human breast cancer. Analysis of 45 cases. Hori M, Furusato M, Nikaidoh T, Aizawa S, Acta Pathol Jpn 1990 40 902 907 1965755
22. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Bhargava V, Kell DL, van de Rijn M, Warnke RA, Am J Pathol 1994 145 535 540 8080038
23. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL, Br J Cancer 1994 69 135 139 10.1038/bjc.1994.22 8286195
24. Cell sensitivity assays: the MTT assay. van Meerloo J, Kaspers GJ, Cloos J, Methods Mol Biol 2011 731 237 245 10.1007/978-1-61779-080-5-20 21516412
25. BCL-2 family: regulators of cell death. Chao DT, Korsmeyer SJ, Annu Rev Immunol 1998 16 395 419 10.1146/annurev.immunol.16.1.395 9597135
26. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Miyashita T, Reed JC, Blood 1993 81 151 157 8417786
27. The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents. Deisseroth AB, DeVita VT, Cancer J Sci Am 1995 1 15 21 9166447
28. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Shah MA, Schwartz GK, Clin Cancer Res 2001 7 2168 2181 11489790
29. Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER. Jeng MH, Jiang SY, Jordan VC, Cancer Lett 1994 82 123 128 10.1016/0304-3835(94)90001-9 8050081
30. Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes. Moggs JG, Murphy TC, Lim FL, Moore DJ, Stuckey R, Antrobus K, Kimber I, Orphanides G, J Mol Endocrinol 2005 34 535 551 10.1677/jme.1.01677 15821115
31. 17 beta-Estradiol-mediated growth inhibition of MDA-MB-468 cells stably transfected with the estrogen receptor: cell cycle effects. Wang W, Smith R, Burghardt R, Safe SH, Mol Cell Endocrinol 1997 133 49 62 10.1016/S0303-7207(97) 00142-1 9359472